Merck Frosst Canada, Inc.

Merck Frosst Canada & Co.

Nanjing Allgen Pharma Co. Ltd.

Merck + Co., Inc.

Merck Frosst Company

Merck Canada Inc.

Astar Biotech LLC

Beta Pharma Canada Inc.

Merck Erosst Canada & Co.

Merck Frosst Canada Inc./merck Frosst Canada & Co.

Zhaoyin Wang

Jacques Yves Gauthier

Serge Leger

Yves Leblanc

Michel Therien

Petpiboon Prasit

Lianhai Li

Cameron Black

Patrick Roy

Claude Dufresne

Cheuk K Lau

Rejean Fortin

Daniel Guay

Yves Ducharme

Erich L Grimm

Claudio F Sturino

Carl Berthelette

Daniel Dube

Chun Sing Li

Richard W Friesen

Christian Beaulieu

Greg Hughes

Yongxin Han

Pierre A Hamel

Christopher I Bayly

Michael Boyd

Nicolas Lachance

Gregory Hughes

Zhigang Wang

Robert N Young

Robert J Zamboni

Joseph G Atkinson

Michel Gallant

John Colucci

Patrick Lacombe

John Scheigetz

Chun-Sing Li

Mario Girard

Renee Aspiotis

Helene Perrier

Chunrong Yu

Ian Street

Nicholas Lachance

Scheigetz John

Claudio Sturino

The present document describes novel molecules having protein tyrosine kinase inhibitory activity, and methods of synthesizing and using such compounds. More specifically, the present document describes compound of Formula (A): (Formula (A)) or a pharmaceutically acceptable salt, hydrate or solvate thereof, and methods of synthesizing and using such compounds. 

Cyclic molecules as bruton's tyrosine kinase inhibitors

The present document describes compounds of Formula I, pharmaceutical compositions comprising the same as well as methods of treating diseases such as a cancer, neurological disease, neurodegenerative disorder, stroke, traumatic brain injury, parasitic infection, inflammation or an autoimmune disease with said compounds. 

Heterocyclic amides compounds which are HDAC6 inhibitors and used as anti-tumoral agents

The present invention relates to spirocyclic compounds of formula I, namely spirocyclic (1H-pyrazol-4-yl)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-2-amines having protein kinase inhibitory activity, and methods of synthesizing and using such compounds. Preferred compounds are c-Met and/or ALK inhibitors useful for the treatment of abnormal cell growth, such as cancers. Ris selected from 

Spirocyclic molecules as protein kinase inhibitors

The present document describes novel compounds which may inhibit the activity of anti-apoptotic proteins such as Bcl-2 family protein members, compositions containing the compounds and methods of treating diseases involving a defect in apoptosis, such as, for example, in the treatment of cancer. 

Heterocyclic molecules as apoptosis inducers

A compound of Formula (I), salts thereof, prodrugs thereof, metabolites thereof, pharmaceutical compositions containing such a compound, and use of such compound and compositions to treat diseases mediated by multiple kinases, such as raf, VEGFR, PDGFR, FLT-3, and c-Kit.

Ureas for the treatment and prevention of cancer

The compound (+) {7R-[[(4-fluorophenyl)sulfonyl] (methyl)ammo]-6,7,8,9-tetrahydropyrido[1,2-a]mdol-10-yl}acetic acid and pharmaceutically acceptable salts thereof are antagonists of the PGD2 receptor, CRTH2, and as such are useful in the treatment and/or prevention of CRTH2-meidated diseases such as asthma. 

Indole derivatives as CRTH2 receptor antagonists

The invention is directed to indole amide derivatives as EP4 receptor antagonists useful for the treatment of EP4 mediated diseases or conditions, such as acute and chronic pain, osteoarthritis, rheumatoid arthritis and cancer. Pharmaceutical compositions and methods of use are also included.

Indole amide derivatives as EP4 receptor antagonists

Compounds according to formula (I) wherein the radicals R, Rand Rare as herein defined, and wherein Ar represents an aryl group or heteroaryl group, preferably phenyl, n is 1 or 2, and the radical X represents a group selected from &#x2014;C(R)(R)&#x2014;, &#x2014;C(R)(R)&#x2014;C(R)(R)&#x2014;, &#x2014;C(R)&#x2550;C(R)&#x2014;, OC(R)(R)&#x2014; or SC(R)(R)&#x2014;. These compounds and their pharmaceutical acceptable salts are used in pharmaceutical compositions as prostaglandine D2 receptor antagonists useful in the treatment of CRTH2-mediated diseases such as respiratory, inflammatory or allergic conditions among others. 

The invention encompasses novel compounds of Formula I, which are nitric oxide-releasing prodrugs of diaryl-2-(5H)-furanones useful in the treatment of cyclooxygenase-2 mediated diseases, Formula (I). The invention also encompasses certain pharmaceutical compositions and methods for treating cyclooxygenase-2 mediated diseases comprising the use of compounds of Formula 1. The above compounds may be used as a combination therapy with low-dose aspirin to treat chronic cyclooxygenase-2 mediated diseases or conditions while also reducing the risk of thrombotic cardiovascular events. 

Nitric oxide releasing prodrugs of diaryl-2-(5H)-furanones as cyclooxygenase-2 inhibitors

The invention encompasses novel compounds of Formula I, which are nitric oxide-releasing prodrugs of diaryl-2-(5H) furanones useful in the treatment of cyclooxygenase-2 mediated diseases. The invention also encompasses certain pharmaceutical compositions and methods for treating cyclooxygenase-2 mediated diseases comprising the use of compounds of Formula I. The above compounds may be used as a combination therapy with low-dose aspirin to treat chronic cyclooxygenase-2 mediated diseases or conditions while also reducing the risk of thrombotic cardiovascular events.

Nitric oxide releasing prodrugs of diaryl-2-(5h)-furanones as cyclooxygenase-2 inhibitors

Fluoro substituted cycloalkanoindole derivatives are antagonists of prostaglandins, and as such are useful for the treatment of prostaglandin mediated diseases.

Fluoro substituted cycloalkanoindoles, compositions containing such compounds and methods of treatment

The invention encompasses novel compounds of Formula I, which are nitric oxide-releasing prodrugs of diaryl-2-(5H) furanones useful in the treatment of cyclooxygenase-2 mediated diseases. The invention also encompasses certain pharmaceutical compositions and methods for treatment of cyclooxygenase-2 mediated diseases comprising the use of compounds of Formula I. The above compounds may be used as a combination therapy with low-dose aspirin to treat chronic cyclooxygenase-2 mediated diseases or conditions while simultaneously reducing the risk of thrombotic cardiovascular events 

Dihydropyrroloindoles and tetrahydropyridoindoles are prostaglandin receptor antagonists useful for the treatment of prostaglandin-mediated diseases such as allergic rhinitis, nasal congestion and asthma.

Dihydropyrrolo[1,2-a]indole and tetrahydropyrido[1,2-a]-indole derivatives as prostaglandin d2 receptor antagonists

Growing community of inventors

Kirkland, Canada

Zhaoyin Wang